Treatment of Pulmonary Neuroendocrine Tumor in Carcinoid Syndrome
Pulmonary neuroendocrine tumors can present with carcinoid syndrome, a clinical picture driven by hormonal hypersecretion — most notably serotonin and related compounds. This scenario requires targeted symptomatic management guided by structured evidence-based protocols.
A subset of pulmonary neuroendocrine tumors are associated with carcinoid syndrome (CS), arising from the secretion of serotonin and other compounds. This hormonal hypersecretion defines a distinct clinical sub-population in which symptomatic control is a primary treatment priority alongside any underlying tumor management.
Symptomatic management of carcinoid syndrome in this setting centres on a specific class of agents used as first-line treatment. The full protocol specifies agent selection, additional perioperative considerations, and the complete evidence-based algorithm.
Full regimen details — including sequencing and clinical decision points — are available via the structured protocol below.
A minority of cases present with symptoms related to hormonal hypersecretion, including carcinoid syndrome (CS), due to serotonin and other compound secretions, Cushing's syndrome (CuS), due to adrenocorticotropic hormone (ACTH) secretion and acromegaly, due to growth hormone-releasing hormone (GHRH) secretion.
Based on approval and recommendations in gastroenteropancreatic (GEP) NET patients with CS, we recommend long-acting SSAs as first-line symptomatic treatment of CS [V, B].
View source ↗